Fulcrum Therapeutics, Inc. (FULC) Q4 2024 Earnings Call Transcript
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET
Company Participants
Alex Sapir – President & CEO
Alan Musso – CFO
Iain Fraser – SVP, Early Development
Conference Call Participants
Rick Miller – Cantor Fitzgerald
Joseph Schwartz – Leerink Partners
Matthew Biegler – Oppenheimer
Edward Tenthoff – Piper Sandler
Anish Nikhanj – RBC Capital
Operator
Good morning, and welcome to Fulcrum Therapeutics Fourth Quarter and Full Year 2024 Financial Results and Business Update Conference Call. Currently, all participants are in listen-only mode. This call is being webcast live and can be accessed on the Investors section of Fulcrum’s website at www.fulcrumtx.com and is being recorded.
Please be reminded that remarks during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. May include statements about the company’s future expectations and plans, clinical development time lines and financial projections. While these forward-looking statements represent Fulcrum’s views as of today, this should not be relied upon as representing the company’s views in the future.
Fulcrum may update these statements in the future, but is not taking on any obligation to do so. Please refer to Fulcrum’s most recent filings with the Securities and Exchange Commission for discussions of certain risks and uncertainties associated with the company’s business.
Leading the call today will be Alex Sapir, CEO and President of Fulcrum. Joining Alex on the call are Alan Musso, Chief Financial Officer; and Dr. Iain Fraser, Senior Vice President of Early Development. After providing updates on the company’s key programs, there will be a brief Q&A, in which Alex, Alan, and Iain will be available to answer your questions.
With that, it’s my pleasure to turn the call over to Alex.
Alex Sapir
That’s great. Thanks so much, Marvin. Good morning, everyone, and thank
